SIGA Technologies
Clinical trials sponsored by SIGA Technologies, explained in plain language.
Develops pharmaceuticals for viral infections, including smallpox treatment TPOXX.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Does a smallpox drug weaken the vaccine? new study aims to find out. Results expected Jan 2027 (estimated)
-
Can an antiviral drug stop smallpox? researchers track survival
Cure CancelledResearchers are observing patients diagnosed with smallpox who receive the antiviral drug tecovirimat (TPOXX). The study tracks how many patients survive at day 44 and monitors safety. Because smallpox is rare, the study relies on cases that occur naturally or in outbreaks, and i…
Sponsor: SIGA Technologies • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
-
Does a smallpox drug weaken the vaccine? new study aims to find out.
Knowledge-focused OngoingThis study looks at whether taking the smallpox drug TPOXX changes how well the JYNNEOS vaccine works. About 100 healthy adults aged 18 to 42 will get two doses of the vaccine and either TPOXX or a placebo for 28 days. Researchers will check for side effects and measure immune re…
Phase 2 • Sponsor: SIGA Technologies • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC